B7688
PiB
≥98% (HPLC)
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula empírica (notación de Hill):
C22H18N2O8
Número CAS:
Peso molecular:
438.39
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleQuality Level
assay
≥98% (HPLC)
form
powder
color
white to light brown
solubility
DMSO: 1-2 mg/mL (warmed)
storage temp.
2-8°C
SMILES string
O=C(C1=C2C(C3=CC=C24)=C(C(N(CC(OCC)=O)C3=O)=O)C=C1)N(CC(OCC)=O)C4=O
InChI
1S/C22H18N2O8/c1-3-31-15(25)9-23-19(27)11-5-7-13-18-14(8-6-12(17(11)18)20(23)28)22(30)24(21(13)29)10-16(26)32-4-2/h5-8H,3-4,9-10H2,1-2H3
InChI key
WNKQGFNIIHNGQM-UHFFFAOYSA-N
Biochem/physiol Actions
PiB is a Pin-1 inhibitor.
PiB is an inhibitor of the peptidylprolyl isomerase Pin-1. Inhibition of Pin-1 leads to destabilization of the transcription factor Nanog, which is required for maintenance of embryonic stem cell cultures.
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Sven H C Askes et al.
Small (Weinheim an der Bergstrasse, Germany), 12(40), 5579-5590 (2016-10-21)
Light upconversion is a very powerful tool in bioimaging as it can eliminate autofluorescence, increase imaging contrast, reduce irradiation damage, and increase excitation penetration depth in vivo. In particular, triplet-triplet annihilation upconverting (TTA-UC) nanoparticles and liposomes offer high upconversion efficiency
Jun Ho Lee et al.
Frontiers in aging neuroscience, 10, 309-309 (2018-10-20)
Background: Given the barriers prohibiting the broader utilization of amyloid imaging and high screening failure rate in clinical trials, an easily available and valid screening method for identifying cognitively impaired patients with cerebral amyloid deposition is needed. Therefore, we developed
Takamasa Yokoi et al.
Frontiers in aging neuroscience, 10, 304-304 (2018-10-23)
Background: Imaging studies in Alzheimer's disease (AD) have yet to answer the underlying questions concerning the relationship among tau retention, neuroinflammation, network disruption and cognitive decline. We compared the spatial retention patterns of 18F-THK5351 and resting state network (RSN) disruption